| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Regenerative Medicine | 33 | 2019 | 201 | 9.450 |
Why?
|
| Tissue Engineering | 42 | 2020 | 656 | 7.350 |
Why?
|
| Extracellular Matrix | 24 | 2020 | 245 | 6.190 |
Why?
|
| Kidney Transplantation | 35 | 2020 | 517 | 6.090 |
Why?
|
| Tissue Scaffolds | 35 | 2020 | 415 | 5.830 |
Why?
|
| Organ Transplantation | 15 | 2019 | 66 | 4.580 |
Why?
|
| Liver Transplantation | 30 | 2019 | 179 | 4.100 |
Why?
|
| Kidney | 17 | 2020 | 515 | 3.790 |
Why?
|
| Regeneration | 17 | 2019 | 170 | 3.200 |
Why?
|
| Bioengineering | 14 | 2017 | 70 | 3.110 |
Why?
|
| Graft Rejection | 14 | 2018 | 238 | 3.040 |
Why?
|
| Immunosuppression | 15 | 2016 | 121 | 2.710 |
Why?
|
| Graft Survival | 20 | 2020 | 314 | 2.330 |
Why?
|
| Biocompatible Materials | 11 | 2019 | 232 | 2.310 |
Why?
|
| Pancreas | 8 | 2020 | 104 | 2.170 |
Why?
|
| Humans | 128 | 2020 | 32024 | 1.970 |
Why?
|
| Stem Cell Transplantation | 10 | 2019 | 209 | 1.830 |
Why?
|
| Immune Tolerance | 8 | 2018 | 71 | 1.820 |
Why?
|
| Immunosuppressive Agents | 15 | 2015 | 240 | 1.700 |
Why?
|
| Tissue Donors | 12 | 2018 | 198 | 1.560 |
Why?
|
| Liver Neoplasms | 6 | 2019 | 159 | 1.470 |
Why?
|
| Animals | 46 | 2019 | 7466 | 1.390 |
Why?
|
| Stem Cells | 11 | 2019 | 313 | 1.330 |
Why?
|
| Kidney Failure, Chronic | 9 | 2020 | 541 | 1.290 |
Why?
|
| Pancreas Transplantation | 8 | 2018 | 247 | 1.260 |
Why?
|
| Kidney Diseases | 4 | 2015 | 249 | 1.200 |
Why?
|
| Postoperative Complications | 9 | 2018 | 785 | 1.170 |
Why?
|
| Hemangiosarcoma | 2 | 2019 | 9 | 1.140 |
Why?
|
| Gastrointestinal Diseases | 3 | 2018 | 43 | 1.110 |
Why?
|
| Transplantation Immunology | 6 | 2017 | 28 | 1.030 |
Why?
|
| Insulin-Secreting Cells | 4 | 2020 | 53 | 0.940 |
Why?
|
| Liver Failure | 5 | 2013 | 20 | 0.900 |
Why?
|
| Islets of Langerhans Transplantation | 6 | 2018 | 47 | 0.880 |
Why?
|
| Liver | 8 | 2015 | 483 | 0.810 |
Why?
|
| Islets of Langerhans | 6 | 2020 | 76 | 0.800 |
Why?
|
| Renal Artery | 3 | 2018 | 47 | 0.770 |
Why?
|
| Adult | 38 | 2020 | 9366 | 0.760 |
Why?
|
| Gastrointestinal Tract | 4 | 2016 | 29 | 0.750 |
Why?
|
| Male | 52 | 2020 | 19195 | 0.750 |
Why?
|
| Hydrogels | 2 | 2019 | 121 | 0.740 |
Why?
|
| Proteome | 1 | 2020 | 39 | 0.730 |
Why?
|
| Gene Expression Profiling | 2 | 2020 | 323 | 0.700 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 61 | 0.680 |
Why?
|
| Tissue and Organ Procurement | 6 | 2018 | 93 | 0.680 |
Why?
|
| RNA | 1 | 2020 | 92 | 0.670 |
Why?
|
| Delayed Graft Function | 6 | 2020 | 33 | 0.660 |
Why?
|
| Bioartificial Organs | 3 | 2014 | 25 | 0.660 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2018 | 251 | 0.630 |
Why?
|
| Middle Aged | 36 | 2020 | 11868 | 0.620 |
Why?
|
| Eubacterium | 2 | 2008 | 2 | 0.620 |
Why?
|
| Cold Ischemia | 1 | 2018 | 7 | 0.620 |
Why?
|
| Gram-Positive Bacterial Infections | 2 | 2008 | 12 | 0.620 |
Why?
|
| Female | 48 | 2020 | 19953 | 0.610 |
Why?
|
| Hepatectomy | 2 | 2008 | 64 | 0.600 |
Why?
|
| Glycosaminoglycans | 1 | 2016 | 20 | 0.570 |
Why?
|
| Transplantation Tolerance | 3 | 2011 | 14 | 0.550 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2017 | 104 | 0.530 |
Why?
|
| Cells, Cultured | 5 | 2019 | 833 | 0.530 |
Why?
|
| Microvessels | 1 | 2015 | 25 | 0.520 |
Why?
|
| Kidney Glomerulus | 1 | 2015 | 30 | 0.510 |
Why?
|
| Mycophenolic Acid | 3 | 2015 | 41 | 0.510 |
Why?
|
| Cephalosporins | 1 | 2014 | 9 | 0.490 |
Why?
|
| Hemodynamics | 1 | 2015 | 155 | 0.490 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2014 | 37 | 0.480 |
Why?
|
| Hepatitis C | 3 | 2011 | 41 | 0.470 |
Why?
|
| Facial Transplantation | 3 | 2018 | 8 | 0.460 |
Why?
|
| Isoantibodies | 1 | 2014 | 12 | 0.460 |
Why?
|
| Bioprosthesis | 1 | 2014 | 58 | 0.460 |
Why?
|
| Follow-Up Studies | 14 | 2019 | 2280 | 0.440 |
Why?
|
| Retrospective Studies | 18 | 2020 | 3523 | 0.440 |
Why?
|
| Spinal Fusion | 3 | 2018 | 41 | 0.440 |
Why?
|
| Gastroenterology | 1 | 2012 | 4 | 0.430 |
Why?
|
| Radiography, Interventional | 2 | 2014 | 37 | 0.430 |
Why?
|
| Abdomen | 1 | 2012 | 44 | 0.420 |
Why?
|
| Prognosis | 8 | 2019 | 1505 | 0.420 |
Why?
|
| Donor Selection | 4 | 2019 | 33 | 0.410 |
Why?
|
| Spectrum Analysis, Raman | 3 | 2020 | 9 | 0.410 |
Why?
|
| Anti-Bacterial Agents | 1 | 2014 | 324 | 0.400 |
Why?
|
| Urinalysis | 3 | 2020 | 27 | 0.390 |
Why?
|
| Treatment Outcome | 18 | 2020 | 3317 | 0.380 |
Why?
|
| General Surgery | 1 | 2012 | 89 | 0.380 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 2 | 2007 | 2 | 0.380 |
Why?
|
| Time Factors | 15 | 2017 | 2152 | 0.370 |
Why?
|
| Clinical Protocols | 1 | 2010 | 99 | 0.360 |
Why?
|
| Scrotum | 1 | 2010 | 7 | 0.360 |
Why?
|
| Hernia | 1 | 2010 | 11 | 0.360 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 288 | 0.360 |
Why?
|
| Ureteral Diseases | 1 | 2010 | 8 | 0.360 |
Why?
|
| Hemorrhage | 2 | 2013 | 100 | 0.350 |
Why?
|
| Aged | 22 | 2020 | 10340 | 0.340 |
Why?
|
| Thoracic Vertebrae | 3 | 2018 | 42 | 0.330 |
Why?
|
| Biopsy, Needle | 2 | 2012 | 95 | 0.330 |
Why?
|
| Carcinoid Tumor | 1 | 2008 | 14 | 0.320 |
Why?
|
| Bone Marrow Transplantation | 2 | 2009 | 63 | 0.320 |
Why?
|
| Recurrence | 7 | 2014 | 265 | 0.320 |
Why?
|
| Aneurysm | 1 | 2008 | 21 | 0.320 |
Why?
|
| Hemothorax | 1 | 2008 | 6 | 0.320 |
Why?
|
| Urinary Tract | 1 | 2008 | 22 | 0.310 |
Why?
|
| Cadaver | 6 | 2018 | 161 | 0.310 |
Why?
|
| Liver Cirrhosis | 4 | 2019 | 82 | 0.310 |
Why?
|
| Pregnancy Complications | 3 | 2015 | 105 | 0.310 |
Why?
|
| Pleural Effusion | 1 | 2008 | 13 | 0.310 |
Why?
|
| Diabetes Mellitus | 3 | 2018 | 411 | 0.310 |
Why?
|
| Liver Diseases | 3 | 2018 | 70 | 0.310 |
Why?
|
| Cell Differentiation | 5 | 2019 | 468 | 0.310 |
Why?
|
| Ureter | 1 | 2008 | 38 | 0.310 |
Why?
|
| Kidney Pelvis | 1 | 2008 | 17 | 0.310 |
Why?
|
| Opportunistic Infections | 1 | 2007 | 17 | 0.300 |
Why?
|
| Sirolimus | 3 | 2013 | 33 | 0.300 |
Why?
|
| Organogenesis | 3 | 2019 | 15 | 0.300 |
Why?
|
| Fever | 1 | 2008 | 61 | 0.300 |
Why?
|
| Scoliosis | 2 | 2017 | 23 | 0.300 |
Why?
|
| Bioreactors | 4 | 2018 | 60 | 0.290 |
Why?
|
| Swine | 7 | 2018 | 215 | 0.290 |
Why?
|
| Tissue Transplantation | 2 | 2018 | 16 | 0.280 |
Why?
|
| Transplantation, Homologous | 3 | 2017 | 151 | 0.280 |
Why?
|
| Intestine, Small | 3 | 2017 | 40 | 0.280 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2008 | 199 | 0.270 |
Why?
|
| Perfusion | 5 | 2019 | 73 | 0.270 |
Why?
|
| Dyslipidemias | 1 | 2007 | 53 | 0.270 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2005 | 3 | 0.270 |
Why?
|
| Hypertension, Portal | 1 | 2005 | 10 | 0.270 |
Why?
|
| Tacrolimus | 3 | 2014 | 65 | 0.270 |
Why?
|
| Organ Culture Techniques | 4 | 2017 | 39 | 0.260 |
Why?
|
| Survival Rate | 6 | 2018 | 885 | 0.260 |
Why?
|
| Forecasting | 2 | 2017 | 144 | 0.260 |
Why?
|
| Vagina | 1 | 2005 | 57 | 0.260 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2015 | 72 | 0.250 |
Why?
|
| Graft vs Host Disease | 1 | 2005 | 21 | 0.250 |
Why?
|
| Quality of Life | 5 | 2015 | 932 | 0.240 |
Why?
|
| Cholangitis | 1 | 2004 | 3 | 0.240 |
Why?
|
| Risk Factors | 8 | 2018 | 3869 | 0.240 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2004 | 8 | 0.240 |
Why?
|
| Portal Vein | 3 | 2013 | 28 | 0.230 |
Why?
|
| History, 20th Century | 3 | 2018 | 71 | 0.230 |
Why?
|
| Hypertension | 2 | 2009 | 957 | 0.220 |
Why?
|
| Young Adult | 11 | 2020 | 2615 | 0.220 |
Why?
|
| Keratins | 2 | 2013 | 39 | 0.220 |
Why?
|
| Biopsy | 6 | 2014 | 260 | 0.220 |
Why?
|
| Transplants | 2 | 2014 | 23 | 0.210 |
Why?
|
| Adolescent | 9 | 2020 | 3526 | 0.210 |
Why?
|
| Kidney Function Tests | 3 | 2018 | 106 | 0.210 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2002 | 5 | 0.210 |
Why?
|
| Registries | 4 | 2016 | 298 | 0.210 |
Why?
|
| Liver Regeneration | 2 | 2012 | 24 | 0.210 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 1428 | 0.200 |
Why?
|
| Glomerular Filtration Rate | 3 | 2018 | 305 | 0.200 |
Why?
|
| Thrombosis | 1 | 2002 | 73 | 0.200 |
Why?
|
| Ear | 2 | 2018 | 18 | 0.200 |
Why?
|
| Rats | 8 | 2018 | 1596 | 0.200 |
Why?
|
| Intestines | 2 | 2012 | 64 | 0.190 |
Why?
|
| Myocardium | 2 | 2019 | 186 | 0.190 |
Why?
|
| Immunohistochemistry | 4 | 2017 | 532 | 0.190 |
Why?
|
| Solubility | 1 | 2020 | 37 | 0.190 |
Why?
|
| Microscopy, Electron, Scanning | 3 | 2015 | 98 | 0.180 |
Why?
|
| Disease Progression | 6 | 2017 | 594 | 0.180 |
Why?
|
| Cyclosporine | 3 | 2011 | 49 | 0.180 |
Why?
|
| Europe | 4 | 2016 | 83 | 0.180 |
Why?
|
| Transplantation, Autologous | 2 | 2017 | 80 | 0.180 |
Why?
|
| Spinal Neoplasms | 1 | 2020 | 22 | 0.180 |
Why?
|
| SOX9 Transcription Factor | 1 | 2019 | 12 | 0.170 |
Why?
|
| Multipotent Stem Cells | 1 | 2019 | 17 | 0.170 |
Why?
|
| Fatal Outcome | 1 | 2019 | 82 | 0.170 |
Why?
|
| Nanomedicine | 1 | 2019 | 16 | 0.170 |
Why?
|
| Radiography | 2 | 2017 | 377 | 0.170 |
Why?
|
| Cell Lineage | 1 | 2019 | 71 | 0.170 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2019 | 69 | 0.170 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2020 | 64 | 0.170 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 89 | 0.170 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 2 | 2012 | 11 | 0.170 |
Why?
|
| Pylorus | 2 | 2015 | 5 | 0.170 |
Why?
|
| Allergy and Immunology | 1 | 2019 | 2 | 0.170 |
Why?
|
| Urine | 1 | 2019 | 64 | 0.160 |
Why?
|
| Nanoparticles | 1 | 2019 | 52 | 0.160 |
Why?
|
| Sterilization | 1 | 2018 | 2 | 0.160 |
Why?
|
| Powders | 1 | 2018 | 8 | 0.160 |
Why?
|
| Neovascularization, Physiologic | 3 | 2014 | 110 | 0.160 |
Why?
|
| Endarterectomy | 1 | 2018 | 6 | 0.160 |
Why?
|
| Transcription Factors | 1 | 2019 | 180 | 0.160 |
Why?
|
| Muscle, Smooth | 2 | 2015 | 70 | 0.160 |
Why?
|
| Child | 4 | 2019 | 2441 | 0.160 |
Why?
|
| Omentum | 2 | 2017 | 26 | 0.150 |
Why?
|
| Child, Preschool | 4 | 2019 | 1269 | 0.150 |
Why?
|
| Kyphosis | 1 | 2018 | 10 | 0.150 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2019 | 81 | 0.150 |
Why?
|
| Alginates | 2 | 2017 | 53 | 0.150 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2020 | 192 | 0.150 |
Why?
|
| Risk Assessment | 4 | 2015 | 1435 | 0.150 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2017 | 54 | 0.150 |
Why?
|
| Pressure | 2 | 2016 | 51 | 0.150 |
Why?
|
| Osteotomy | 1 | 2018 | 51 | 0.150 |
Why?
|
| Infant | 3 | 2019 | 1061 | 0.150 |
Why?
|
| Collagen | 3 | 2014 | 225 | 0.140 |
Why?
|
| Insulin | 2 | 2016 | 366 | 0.140 |
Why?
|
| Osmotic Pressure | 1 | 2017 | 10 | 0.140 |
Why?
|
| Implants, Experimental | 1 | 2016 | 12 | 0.140 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 132 | 0.140 |
Why?
|
| Esophagogastric Junction | 1 | 2016 | 7 | 0.140 |
Why?
|
| Immunomodulation | 1 | 2017 | 32 | 0.140 |
Why?
|
| Nephrectomy | 2 | 2016 | 123 | 0.140 |
Why?
|
| Apolipoproteins | 2 | 2016 | 200 | 0.140 |
Why?
|
| Macrophage Activation | 1 | 2016 | 11 | 0.140 |
Why?
|
| Cell Proliferation | 2 | 2016 | 599 | 0.140 |
Why?
|
| Cells, Immobilized | 1 | 2017 | 23 | 0.140 |
Why?
|
| Nephritis, Hereditary | 1 | 2016 | 3 | 0.140 |
Why?
|
| Living Donors | 2 | 2015 | 64 | 0.140 |
Why?
|
| Hemostasis | 2 | 2013 | 6 | 0.140 |
Why?
|
| Lipoproteins, HDL | 2 | 2016 | 251 | 0.140 |
Why?
|
| Cell Separation | 1 | 2017 | 93 | 0.140 |
Why?
|
| Hemangioendothelioma, Epithelioid | 2 | 2007 | 3 | 0.140 |
Why?
|
| Immunocompetence | 2 | 2014 | 11 | 0.140 |
Why?
|
| Survival Analysis | 3 | 2019 | 488 | 0.140 |
Why?
|
| Antigens, Differentiation | 1 | 2015 | 25 | 0.130 |
Why?
|
| Prospective Studies | 5 | 2018 | 2283 | 0.130 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2015 | 1 | 0.130 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2015 | 3 | 0.130 |
Why?
|
| History, 21st Century | 2 | 2018 | 59 | 0.130 |
Why?
|
| Protein Array Analysis | 1 | 2015 | 16 | 0.130 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 21 | 0.130 |
Why?
|
| Corrosion Casting | 1 | 2015 | 10 | 0.130 |
Why?
|
| Enteric Nervous System | 1 | 2015 | 1 | 0.130 |
Why?
|
| Chitosan | 1 | 2015 | 3 | 0.130 |
Why?
|
| Caveolin 1 | 1 | 2015 | 13 | 0.130 |
Why?
|
| Uremia | 1 | 2015 | 9 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 242 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 111 | 0.120 |
Why?
|
| C-Peptide | 1 | 2014 | 29 | 0.120 |
Why?
|
| Lung | 2 | 2015 | 255 | 0.120 |
Why?
|
| Macrophages | 1 | 2016 | 192 | 0.120 |
Why?
|
| Transplantation Conditioning | 1 | 2014 | 13 | 0.120 |
Why?
|
| Mice | 4 | 2017 | 2475 | 0.120 |
Why?
|
| Steroids | 1 | 2014 | 38 | 0.120 |
Why?
|
| Fibrosis | 2 | 2014 | 118 | 0.120 |
Why?
|
| Antilymphocyte Serum | 1 | 2014 | 39 | 0.120 |
Why?
|
| Polyglycolic Acid | 1 | 2014 | 33 | 0.120 |
Why?
|
| Ossification, Heterotopic | 1 | 2014 | 18 | 0.120 |
Why?
|
| Perioperative Care | 1 | 2014 | 59 | 0.120 |
Why?
|
| Muscles | 1 | 2014 | 62 | 0.120 |
Why?
|
| Age Factors | 5 | 2019 | 1194 | 0.120 |
Why?
|
| Embolization, Therapeutic | 1 | 2014 | 87 | 0.110 |
Why?
|
| Cell-Free System | 2 | 2015 | 15 | 0.110 |
Why?
|
| Guided Tissue Regeneration | 1 | 2014 | 38 | 0.110 |
Why?
|
| Heart | 2 | 2015 | 179 | 0.110 |
Why?
|
| Waiting Lists | 1 | 2013 | 34 | 0.110 |
Why?
|
| Regional Blood Flow | 1 | 2013 | 86 | 0.110 |
Why?
|
| Creatinine | 4 | 2019 | 195 | 0.110 |
Why?
|
| Polyurethanes | 1 | 2013 | 5 | 0.110 |
Why?
|
| Drainage | 1 | 2013 | 72 | 0.110 |
Why?
|
| Antigens | 1 | 2013 | 31 | 0.110 |
Why?
|
| Chickens | 1 | 2013 | 38 | 0.110 |
Why?
|
| Hemostatics | 1 | 2013 | 11 | 0.110 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 1017 | 0.110 |
Why?
|
| Esophageal Diseases | 1 | 2012 | 7 | 0.110 |
Why?
|
| Hair | 1 | 2013 | 28 | 0.110 |
Why?
|
| Esophagus | 1 | 2012 | 22 | 0.110 |
Why?
|
| Aortic Rupture | 1 | 2012 | 7 | 0.110 |
Why?
|
| Urinary Bladder | 1 | 2014 | 182 | 0.100 |
Why?
|
| Hepatitis C, Chronic | 1 | 2012 | 77 | 0.100 |
Why?
|
| Larynx | 1 | 2012 | 20 | 0.100 |
Why?
|
| Chondroitin Sulfates | 1 | 2012 | 21 | 0.100 |
Why?
|
| Skin, Artificial | 1 | 2012 | 33 | 0.100 |
Why?
|
| Hepatocytes | 1 | 2012 | 76 | 0.100 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2014 | 182 | 0.100 |
Why?
|
| Pancreatic Diseases | 1 | 2012 | 18 | 0.100 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2012 | 49 | 0.100 |
Why?
|
| Respiratory Tract Diseases | 1 | 2012 | 34 | 0.100 |
Why?
|
| Intestinal Diseases | 1 | 2012 | 16 | 0.100 |
Why?
|
| Cell Transplantation | 1 | 2012 | 64 | 0.100 |
Why?
|
| Pregnancy | 4 | 2019 | 994 | 0.100 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2012 | 83 | 0.100 |
Why?
|
| Developmental Biology | 1 | 2011 | 6 | 0.100 |
Why?
|
| African Americans | 2 | 2016 | 1428 | 0.100 |
Why?
|
| Cattle | 1 | 2011 | 103 | 0.100 |
Why?
|
| Sarcoidosis | 1 | 2011 | 27 | 0.100 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 300 | 0.100 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2010 | 5 | 0.090 |
Why?
|
| Corneal Transplantation | 1 | 2010 | 14 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 1067 | 0.090 |
Why?
|
| Chondrocytes | 1 | 2011 | 74 | 0.090 |
Why?
|
| Wound Healing | 1 | 2012 | 185 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 68 | 0.090 |
Why?
|
| Trachea | 1 | 2010 | 54 | 0.090 |
Why?
|
| Discriminant Analysis | 2 | 2020 | 21 | 0.090 |
Why?
|
| Principal Component Analysis | 2 | 2020 | 68 | 0.090 |
Why?
|
| Phenotype | 3 | 2016 | 639 | 0.090 |
Why?
|
| Brachiocephalic Veins | 1 | 2009 | 8 | 0.090 |
Why?
|
| Cell Survival | 3 | 2017 | 286 | 0.080 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2009 | 5 | 0.080 |
Why?
|
| Incidence | 3 | 2018 | 1200 | 0.080 |
Why?
|
| Arteriovenous Fistula | 1 | 2009 | 18 | 0.080 |
Why?
|
| Wounds and Injuries | 1 | 2012 | 253 | 0.080 |
Why?
|
| Cell Fractionation | 1 | 2009 | 8 | 0.080 |
Why?
|
| Hand | 1 | 2009 | 66 | 0.080 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2009 | 48 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2010 | 224 | 0.080 |
Why?
|
| Retroperitoneal Space | 1 | 2008 | 20 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 594 | 0.080 |
Why?
|
| Abdominal Pain | 1 | 2008 | 45 | 0.080 |
Why?
|
| Thoracic Wall | 1 | 2008 | 7 | 0.080 |
Why?
|
| Sex Distribution | 1 | 2008 | 195 | 0.080 |
Why?
|
| Age Distribution | 1 | 2008 | 207 | 0.080 |
Why?
|
| Diaphragm | 1 | 2008 | 40 | 0.080 |
Why?
|
| Anastomosis, Surgical | 1 | 2008 | 61 | 0.080 |
Why?
|
| Arteries | 1 | 2008 | 67 | 0.080 |
Why?
|
| Neoplasms, Vascular Tissue | 1 | 2007 | 7 | 0.070 |
Why?
|
| United States | 4 | 2017 | 3938 | 0.070 |
Why?
|
| North Carolina | 3 | 2018 | 1516 | 0.070 |
Why?
|
| Rabbits | 3 | 2014 | 196 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 217 | 0.070 |
Why?
|
| Withholding Treatment | 1 | 2006 | 11 | 0.070 |
Why?
|
| Rats, Nude | 2 | 2017 | 43 | 0.070 |
Why?
|
| Rats, Wistar | 2 | 2018 | 79 | 0.070 |
Why?
|
| Postoperative Period | 2 | 2017 | 97 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 687 | 0.070 |
Why?
|
| Triglycerides | 1 | 2007 | 230 | 0.070 |
Why?
|
| Heart Failure | 1 | 2012 | 636 | 0.070 |
Why?
|
| Models, Animal | 2 | 2017 | 164 | 0.070 |
Why?
|
| Hexuronic Acids | 2 | 2017 | 31 | 0.070 |
Why?
|
| Glucuronic Acid | 2 | 2017 | 31 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 4000 | 0.070 |
Why?
|
| Cytokines | 2 | 2017 | 260 | 0.060 |
Why?
|
| Hysterectomy | 1 | 2005 | 45 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2012 | 1831 | 0.060 |
Why?
|
| Case-Control Studies | 3 | 2015 | 897 | 0.060 |
Why?
|
| Cholesterol | 1 | 2007 | 251 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2018 | 544 | 0.060 |
Why?
|
| Vena Cava, Inferior | 1 | 2005 | 32 | 0.060 |
Why?
|
| Patient Selection | 2 | 2018 | 277 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 298 | 0.060 |
Why?
|
| Bile Reflux | 1 | 2004 | 1 | 0.060 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2004 | 6 | 0.060 |
Why?
|
| Reoperation | 2 | 2016 | 227 | 0.060 |
Why?
|
| Rats, Inbred Lew | 2 | 2015 | 117 | 0.060 |
Why?
|
| Heparitin Sulfate | 1 | 2004 | 1 | 0.060 |
Why?
|
| Integrin alphaV | 1 | 2004 | 2 | 0.060 |
Why?
|
| Transgenes | 1 | 2004 | 48 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 900 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2016 | 474 | 0.060 |
Why?
|
| Adenoviridae | 1 | 2004 | 66 | 0.060 |
Why?
|
| Genetic Vectors | 1 | 2004 | 120 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 757 | 0.060 |
Why?
|
| Immunophenotyping | 2 | 2016 | 51 | 0.050 |
Why?
|
| Pregnancy Outcome | 2 | 2015 | 90 | 0.050 |
Why?
|
| DNA | 2 | 2018 | 228 | 0.050 |
Why?
|
| Splenectomy | 1 | 2002 | 21 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2017 | 294 | 0.050 |
Why?
|
| Liver Function Tests | 2 | 2014 | 22 | 0.050 |
Why?
|
| Cystoscopy | 1 | 2020 | 27 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2014 | 526 | 0.050 |
Why?
|
| Metabolome | 1 | 2020 | 36 | 0.050 |
Why?
|
| Equipment Failure | 1 | 2020 | 26 | 0.040 |
Why?
|
| Metabolomics | 1 | 2020 | 54 | 0.040 |
Why?
|
| Dialysis Solutions | 1 | 2020 | 6 | 0.040 |
Why?
|
| Spine | 1 | 2020 | 41 | 0.040 |
Why?
|
| Glycosuria | 1 | 2019 | 3 | 0.040 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2019 | 23 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 878 | 0.040 |
Why?
|
| Peritoneal Dialysis | 1 | 2020 | 26 | 0.040 |
Why?
|
| Urea | 1 | 2019 | 37 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 247 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2019 | 53 | 0.040 |
Why?
|
| Boston | 1 | 2018 | 15 | 0.040 |
Why?
|
| Pluripotent Stem Cells | 1 | 2018 | 18 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2018 | 40 | 0.040 |
Why?
|
| Ischemia | 1 | 2019 | 98 | 0.040 |
Why?
|
| Medical Illustration | 1 | 2018 | 6 | 0.040 |
Why?
|
| Fluoroscopy | 1 | 2018 | 40 | 0.040 |
Why?
|
| Stress, Mechanical | 1 | 2018 | 92 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2018 | 56 | 0.040 |
Why?
|
| Reperfusion | 1 | 2017 | 21 | 0.040 |
Why?
|
| Sex Factors | 2 | 2012 | 663 | 0.040 |
Why?
|
| Rotation | 1 | 2017 | 47 | 0.040 |
Why?
|
| Bone Screws | 1 | 2018 | 57 | 0.040 |
Why?
|
| Adipocytes | 1 | 2018 | 80 | 0.040 |
Why?
|
| Casts, Surgical | 1 | 2017 | 20 | 0.040 |
Why?
|
| Receptors, Cholinergic | 1 | 2017 | 22 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 918 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 370 | 0.040 |
Why?
|
| Hepacivirus | 2 | 2008 | 39 | 0.040 |
Why?
|
| Lumbar Vertebrae | 1 | 2017 | 100 | 0.040 |
Why?
|
| Tensile Strength | 1 | 2016 | 53 | 0.040 |
Why?
|
| Drug Compounding | 1 | 2017 | 37 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 91 | 0.040 |
Why?
|
| Collagen Type I | 1 | 2016 | 42 | 0.030 |
Why?
|
| Polyesters | 1 | 2016 | 76 | 0.030 |
Why?
|
| Tetrodotoxin | 1 | 2015 | 11 | 0.030 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 2015 | 3 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 99 | 0.030 |
Why?
|
| Neurogenesis | 1 | 2015 | 16 | 0.030 |
Why?
|
| Gestational Age | 1 | 2015 | 120 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 155 | 0.030 |
Why?
|
| Muscle Development | 1 | 2015 | 49 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2015 | 43 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 35 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 2015 | 104 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 2015 | 114 | 0.030 |
Why?
|
| Vasodilation | 1 | 2015 | 93 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 146 | 0.030 |
Why?
|
| Haplotypes | 1 | 2015 | 220 | 0.030 |
Why?
|
| Placebos | 1 | 2014 | 63 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2015 | 97 | 0.030 |
Why?
|
| Metaplasia | 1 | 2014 | 19 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2014 | 49 | 0.030 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2014 | 9 | 0.030 |
Why?
|
| Cytomegalovirus Infections | 1 | 2014 | 48 | 0.030 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2014 | 14 | 0.030 |
Why?
|
| Actins | 1 | 2014 | 52 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2014 | 74 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2014 | 163 | 0.030 |
Why?
|
| Organoids | 1 | 2015 | 94 | 0.030 |
Why?
|
| Genotype | 1 | 2016 | 734 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 766 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2014 | 115 | 0.030 |
Why?
|
| Chorioallantoic Membrane | 1 | 2013 | 4 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2018 | 845 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2013 | 32 | 0.030 |
Why?
|
| Chick Embryo | 1 | 2013 | 74 | 0.030 |
Why?
|
| Detergents | 1 | 2013 | 16 | 0.030 |
Why?
|
| Fertility | 1 | 2013 | 31 | 0.030 |
Why?
|
| Sus scrofa | 1 | 2013 | 46 | 0.030 |
Why?
|
| Colorimetry | 1 | 2013 | 3 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2013 | 77 | 0.030 |
Why?
|
| Peristalsis | 1 | 2012 | 1 | 0.030 |
Why?
|
| Rome | 1 | 2012 | 2 | 0.030 |
Why?
|
| Electrophoresis | 1 | 2013 | 7 | 0.030 |
Why?
|
| Length of Stay | 1 | 2014 | 318 | 0.030 |
Why?
|
| Rheology | 1 | 2013 | 30 | 0.030 |
Why?
|
| Extremities | 1 | 2013 | 51 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 65 | 0.030 |
Why?
|
| Blood Platelets | 1 | 2013 | 39 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2012 | 32 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2013 | 108 | 0.030 |
Why?
|
| Capsules | 1 | 2012 | 15 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2013 | 103 | 0.030 |
Why?
|
| Emergencies | 1 | 2012 | 47 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2013 | 292 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 273 | 0.030 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2011 | 4 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2014 | 492 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2011 | 38 | 0.020 |
Why?
|
| Bile Duct Diseases | 1 | 2011 | 10 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2011 | 46 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2014 | 347 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 629 | 0.020 |
Why?
|
| European Continental Ancestry Group | 1 | 2015 | 1169 | 0.020 |
Why?
|
| Inflammation | 1 | 2014 | 540 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2011 | 108 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2012 | 745 | 0.020 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2008 | 4 | 0.020 |
Why?
|
| Biomedical Engineering | 1 | 2009 | 26 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2011 | 673 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2008 | 3 | 0.020 |
Why?
|
| Models, Immunological | 1 | 2008 | 9 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2008 | 25 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2008 | 54 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2008 | 94 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 161 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 137 | 0.020 |
Why?
|
| Bile | 1 | 2006 | 7 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 94 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2006 | 48 | 0.020 |
Why?
|
| Lipids | 1 | 2006 | 229 | 0.020 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2004 | 1 | 0.010 |
Why?
|
| Immunochemistry | 1 | 2004 | 8 | 0.010 |
Why?
|
| Virion | 1 | 2004 | 7 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2004 | 20 | 0.010 |
Why?
|
| Receptors, Peptide | 1 | 2004 | 6 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 2004 | 21 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2004 | 40 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 2004 | 42 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2006 | 508 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2004 | 319 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2004 | 518 | 0.010 |
Why?
|